Volume 2020, Issue 1 1380176

Research Article

Open Access

Pentraxin 3 Levels in Young Women with and without Polycystic Ovary Syndrome (PCOS) in relation to the Nutritional Status and Systemic Inflammation

Katarzyna Wyskida

Health Promotion and Obesity Management Unit, Department of Pathophysiology, Medical Faculty in Katowice, The Medical University of Silesia, Katowice, Poland

Search for more papers by this author

Grzegorz Franik,

Grzegorz Franik

Department of Gynecological Endocrinology, Medical Faculty in Katowice, The Medical University of Silesia, Katowice, Poland

Search for more papers by this author

Piotr Choręza,

Piotr Choręza

Department of Statistics, Department of Instrumental Analysis, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Katowice, Poland sum.edu.pl

Search for more papers by this author

Natalia Pohl,

Natalia Pohl

Department of Statistics, Department of Instrumental Analysis, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Katowice, Poland sum.edu.pl

Search for more papers by this author

Leszek Markuszewski,

Leszek Markuszewski

Center Heart and Vascular Diseases, Internal and Metabolic Diseases, Mazovian Specialist Hospital in Radom, Radom, Poland

Search for more papers by this author

Aleksander Owczarek,

Aleksander Owczarek

Pathophysiology Unit, Department of Pathophysiology, Medical Faculty in Katowice, The Medical University of Silesia, Katowice, Poland

Search for more papers by this author

Paweł Madej,

Paweł Madej

Department of Gynecological Endocrinology, Medical Faculty in Katowice, The Medical University of Silesia, Katowice, Poland

Search for more papers by this author

Jerzy Chudek,

Jerzy Chudek

Pathophysiology Unit, Department of Pathophysiology, Medical Faculty in Katowice, The Medical University of Silesia, Katowice, Poland

Department of Internal Medicine and Oncological Chemotherapy, Medical Faculty in Katowice, The Medical University of Silesia, Katowice, Poland

Search for more papers by this author

Magdalena Olszanecka-Glinianowicz,

Corresponding Author

Magdalena Olszanecka-Glinianowicz

[email protected]

orcid.org/0000-0001-5632-5590

Health Promotion and Obesity Management Unit, Department of Pathophysiology, Medical Faculty in Katowice, The Medical University of Silesia, Katowice, Poland

Search for more papers by this author

Katarzyna Wyskida,

Katarzyna Wyskida

Health Promotion and Obesity Management Unit, Department of Pathophysiology, Medical Faculty in Katowice, The Medical University of Silesia, Katowice, Poland

Search for more papers by this author

Grzegorz Franik,

Grzegorz Franik

Department of Gynecological Endocrinology, Medical Faculty in Katowice, The Medical University of Silesia, Katowice, Poland

Search for more papers by this author

Piotr Choręza,

Piotr Choręza

Department of Statistics, Department of Instrumental Analysis, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Katowice, Poland sum.edu.pl

Search for more papers by this author

Natalia Pohl,

Natalia Pohl

Department of Statistics, Department of Instrumental Analysis, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Katowice, Poland sum.edu.pl

Search for more papers by this author

Leszek Markuszewski,

Leszek Markuszewski

Center Heart and Vascular Diseases, Internal and Metabolic Diseases, Mazovian Specialist Hospital in Radom, Radom, Poland

Search for more papers by this author

Aleksander Owczarek,

Aleksander Owczarek

Pathophysiology Unit, Department of Pathophysiology, Medical Faculty in Katowice, The Medical University of Silesia, Katowice, Poland

Search for more papers by this author

Paweł Madej,

Paweł Madej

Department of Gynecological Endocrinology, Medical Faculty in Katowice, The Medical University of Silesia, Katowice, Poland

Search for more papers by this author

Jerzy Chudek,

Jerzy Chudek

Pathophysiology Unit, Department of Pathophysiology, Medical Faculty in Katowice, The Medical University of Silesia, Katowice, Poland

Department of Internal Medicine and Oncological Chemotherapy, Medical Faculty in Katowice, The Medical University of Silesia, Katowice, Poland

Search for more papers by this author

Magdalena Olszanecka-Glinianowicz,

Corresponding Author

Magdalena Olszanecka-Glinianowicz

[email protected]

orcid.org/0000-0001-5632-5590

Health Promotion and Obesity Management Unit, Department of Pathophysiology, Medical Faculty in Katowice, The Medical University of Silesia, Katowice, Poland

Search for more papers by this author

First published: 02 September 2020

https://doi.org/10.1155/2020/1380176

Citations: 7

Academic Editor: Arturo Bevilacqua

Share a link

Email
Wechat
Bluesky

Abstract

Objective. The aim of the study was to assess PTX3 levels in PCOS and non-PCOS women in relation to nutritional status and circulating markers of inflammation. Methods. The study enrolled 99 stable body mass PCOS women (17 normal weight, 21 overweight, and 61 obese) and 61 non-PCOS women (24 normal weight, 19 overweight, and 18 obese). Body composition was assessed by bioimpedance, and plasma levels of pentraxin 3 (PTX3), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and monocyte chemoattractant protein 1 (MCP-1) were measured. Homeostatic model assessment of insulin resistance (HOMA-IR) was made. Results. Plasma PTX3, TNF-α, and IL-6 levels and HOMA-IR were higher in PCOS than in non-PCOS group (p < 0.001). There were positive correlations between log₁₀ (PTX3) and log₁₀ (BMI), waist circumference and fat percentage, as well as log₁₀ (HOMA-IR) and free androgen index but negative between log₁₀ (estradiol) levels in PCOS. While in the non-PCOS group, the correlations between log₁₀ (PTX3) and log₁₀ (BMI), waist circumference and fat percentage, as well as log₁₀ (HOMA-IR) were negative. The positive correlations between PTX3 and MPC-1 and log₁₀ (IL-6) were shown in the PCOS group only. In multivariate regression analyses, variability in PTX3 levels in the PCOS group was proportional to log₁₀ (BMI), waist circumference, and fat percentage, but inversely proportional to log₁₀ (estradiol) levels. While in the non-PCOS group, PTX3 levels were inversely proportional to all anthropometric parameters. Conclusions. Our results show that the decrease in PTX3 levels observed in obese is distorted in PCOS by microinflammation, and possibly, dysfunction of stroma adipose tissue and liver steatosis is reflected by enhanced insulin resistance.

Conflicts of Interest

The authors declare no conflicts of interest.

Open Research

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

References

1 Liu S., Qu X., Liu F., and Wang C., Pentraxin 3 as a prognostic biomarker in patients with systemic inflammation or infection, Mediators of Inflammation. (2014) 2014, 9, 421429, https://doi.org/10.1155/2014/421429, 2-s2.0-84960866929.
10.1155/2014/421429
CAS PubMed Web of Science® Google Scholar
2 Kunes P., Holubcova Z., Kolackova M., and Krejsek J., Pentraxin 3. (PTX 3): an endogenous modulator of the inflammatory response, Mediators of Inflammation. (2012) 2012, 10, 920517, https://doi.org/10.1155/2012/920517, 2-s2.0-84861090712.
10.1155/2012/920517
CAS PubMed Web of Science® Google Scholar
3 Savchenko A., Imamura M., Ohashi R. et al., Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions, The Journal of Pathology. (2008) 215, no. 1, 48–55, https://doi.org/10.1002/path.2314, 2-s2.0-42949124339.
10.1002/path.2314
CAS PubMed Web of Science® Google Scholar
4 Doni A., Michela M., Bottazzi B. et al., Regulation of PTX3, a key component of humoral innate immunity in human dendritic cells: stimulation by IL-10 and inhibition by IFN, Journal of Leukocyte Biology. (2006) 79, no. 4, 797–802, https://doi.org/10.1189/jlb.0905493, 2-s2.0-33746461007.
10.1189/jlb.0905493
CAS PubMed Web of Science® Google Scholar
5 Abderrahim-Ferkoune A., Bezy O., Chiellini C. et al., Characterization of the long pentraxin PTX3 as a TNFα-induced secreted protein of adipose cells, Journal of Lipid Research. (2003) 44, no. 5, 994–1000, https://doi.org/10.1194/jlr.m200382-jlr200, 2-s2.0-10744233013.
10.1194/jlr.M200382-JLR200
CAS PubMed Web of Science® Google Scholar
6 Olszanecka-Glinianowicz M., Banaś M., Zahorska-Markiewicz B. et al., Is the polycystic ovary syndrome associated with chronic inflammation per se?, European Journal of Obstetrics & Gynecology and Reproductive Biology. (2007) 133, no. 2, 197–202, https://doi.org/10.1016/j.ejogrb.2006.10.037, 2-s2.0-34447520579.
10.1016/j.ejogrb.2006.10.037
CAS PubMed Web of Science® Google Scholar
7 Kelly C. C. J., Lyall H., Petrie J. R., Gould G. W., Connell J. M. C., and Sattar N., Low grade chronic inflammation in women with polycystic ovarian syndrome, The Journal of Clinical Endocrinology & Metabolism. (2001) 86, no. 6, 2453–2455, https://doi.org/10.1210/jcem.86.6.7580, 2-s2.0-0034971531.
10.1210/jcem.86.6.7580
CAS PubMed Web of Science® Google Scholar
8 Escobar-Morreale H. F., Luque-Ramírez M., and González F., Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis, Fertility and Sterility. (2011) 95, no. 3, 1048–1058, https://doi.org/10.1016/j.fertnstert.2010.11.036, 2-s2.0-79951956890.
10.1016/j.fertnstert.2010.11.036
CAS PubMed Web of Science® Google Scholar
9 Aydogdu A., Tasci I., Tapan S. et al., High plasma level of long pentraxin 3 is associated with insulin resistance in women with polycystic ovary syndrome, Gynecological Endocrinology. (2012) 28, no. 9, 722–725, https://doi.org/10.3109/09513590.2011.652719, 2-s2.0-84865331480.
10.3109/09513590.2011.652719
CAS PubMed Web of Science® Google Scholar
10 Deveer M., Deveer R., Basaran O. et al., Serum copeptin, pentraxin 3, anti-mullerian hormone levels with echocardiography and carotid artery intima-media thickness in adolescents with polycystic ovary syndrome, Journal of Clinical Medicine Research. (2015) 7, no. 12, 989–994, https://doi.org/10.14740/jocmr2375w.
10.14740/jocmr2375w
PubMed Google Scholar
11 Sahin F. K., Sahin S. B., Balik G. et al., Does low pentraxin-3 levels associate with polycystic ovary syndrome and obesity?, International Journal of Clinical and Experimental Medicine. (2014) 7, no. 10, 3512–3519.
PubMed Web of Science® Google Scholar
12 Sari U., Kaygusuz I., and Kafali H., Is pentraxin 3 a new cardiovascular risk marker in polycystic ovary syndrome?, Gynecologic and Obstetric Investigation. (2014) 78, no. 3, 173–178, https://doi.org/10.1159/000363744, 2-s2.0-84908665016.
10.1159/000363744
CAS PubMed Web of Science® Google Scholar
13 Tosi F., Di Sarra D., Bonin C. et al., Plasma levels of pentraxin-3, an inflammatory protein involved in fertility, are reduced in women with polycystic ovary syndrome, European Journal of Endocrinology. (2014) 170, no. 3, 401–409, https://doi.org/10.1530/eje-13-0761, 2-s2.0-84896282570.
10.1530/EJE-13-0761
CAS PubMed Web of Science® Google Scholar
14 Slusher A. L., Huang C. J., and Acevedo E. O., The potential role of aerobic exercise-induced pentraxin 3 on obesity-related inflammation and metabolic dysregulation, Mediators of Inflammation. (2017) 2017, 9, 1092738, https://doi.org/10.1155/2017/1092738, 2-s2.0-85017186734.
10.1155/2017/1092738
PubMed Web of Science® Google Scholar
15 Miyazaki T., Chiuve S., Sacks F. M., Ridker P. M., Libby P., and Aikawa M., Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial, PLoS One. (2014) 9, no. 4, e94073, https://doi.org/10.1371/journal.pone.0094073, 2-s2.0-84899055940.
10.1371/journal.pone.0094073
PubMed Web of Science® Google Scholar
16 Witasp A., Carrero J. J., Michaëlsson K. et al., Inflammatory biomarker pentraxin 3 (PTX3) in relation to obesity, body fat depots and weight loss, Obesity. (2014) 22, no. 5, 1373–1379, https://doi.org/10.1002/oby.20695, 2-s2.0-84899989672.
10.1002/oby.20695
CAS PubMed Web of Science® Google Scholar
17 Barazzoni R., Palmisano S., Cappellari G. G. et al., Gastric bypass-induced weight loss alters obesity-associated patterns of plasma pentraxin-3 and systemic inflammatory markers, Surgery for Obesity and Related Diseases. (2016) 12, no. 1, 23–32, https://doi.org/10.1016/j.soard.2015.04.013, 2-s2.0-84959508733.
10.1016/j.soard.2015.04.013
PubMed Web of Science® Google Scholar
18 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome, Fertility and Sterility. (2004) 81, no. 1, 19–25, https://doi.org/10.1016/j.fertnstert.2003.10.004, 2-s2.0-0346725827.
10.1016/j.fertnstert.2003.10.004
PubMed Web of Science® Google Scholar
19 Salgado A. L. F. D. A., Carvalho L. D., Oliveira A. C., Santos V. N. D., Vieira J. G., and Parise E. R., Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals, Arquivos de Gastroenterologia. (2010) 47, no. 2, 165–169, https://doi.org/10.1590/s0004-28032010000200009, 2-s2.0-77957295687.
10.1590/S0004-28032010000200009
PubMed Google Scholar
20 Obesity. Preventing and Managing the Global Epidemic, 1998, Report of a WHO, Geneva, Switzerland.
Google Scholar
21 Osorio-Conles O., Guitart M., Chacón M. R. et al., Plasma PTX3 protein levels inversely correlate with insulin secretion and obesity, whereas visceral adipose tissue PTX3 gene expression is increased in obesity, American Journal of Physiology-Endocrinology and Metabolism. (2011) 301, no. 6, E1254–E1261, https://doi.org/10.1152/ajpendo.00163.2011, 2-s2.0-82355187955.
10.1152/ajpendo.00163.2011
CAS PubMed Web of Science® Google Scholar
22 Orlik B., Madej P., Owczarek A., Skałba P., Chudek J., and Olszanecka-Glinianowicz M., Plasma omentin and adiponectin levels as markers of adipose tissue dysfunction in normal weight and obese women with polycystic ovary syndrome, Clinical Endocrinology. (2014) 81, no. 4, 529–535, https://doi.org/10.1111/cen.12381, 2-s2.0-84908109642.
10.1111/cen.12381
CAS PubMed Web of Science® Google Scholar
23 Boga S., Koksal A. R., Alkim H. et al., Plasma pentraxin 3 differentiates nonalcoholic steatohepatitis (NASH) from non-NASH, Metabolic Syndrome and Related Disorders. (2015) 13, no. 9, 393–399, https://doi.org/10.1089/met.2015.0046, 2-s2.0-84946733444.
10.1089/met.2015.0046
CAS PubMed Web of Science® Google Scholar
24 Hamza R. T., Elfaramawy A. A., and Mahmoud N. H., Serum pentraxin 3 fragment as a noninvasive marker of nonalcoholic fatty liver disease in obese children and adolescents, Hormone Research in Paediatrics. (2016) 86, no. 1, 11–20, https://doi.org/10.1159/000446566, 2-s2.0-84976332618.
10.1159/000446566
CAS PubMed Web of Science® Google Scholar
25 Wu J., Yao X. Y., Shi R. X., Liu S. F., and Wang X. Y., A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis, Reproductive Health. (2018) 15, no. 1, https://doi.org/10.1186/s12978-018-0519-2, 2-s2.0-85046837763.
10.1186/s12978-018-0519-2
Web of Science® Google Scholar
26 Usta A., Avci E., Bulbul C. B., Kadi H., and Adali E., The monocyte counts to HDL cholesterol ratio in obese and lean patients with polycystic ovary syndrome, Reproductive Biology and Endocrinology. (2018) 16, no. 1, https://doi.org/10.1186/s12958-018-0351-0, 2-s2.0-85045203375.
10.1186/s12958-018-0351-0
Web of Science® Google Scholar
27 Jenny N. S., Blumenthal R. S., Kronmal R. A., Rotter J. I., Siscovick D. S., and Psaty B. M., Associations of pentraxin 3 with cardiovascular disease: the multi-ethnic study of atherosclerosis, Journal of Thrombosis and Haemostasis. (2014) 12, no. 6, 999–1005, https://doi.org/10.1111/jth.12557, 2-s2.0-84902120328.
10.1111/jth.12557
CAS PubMed Web of Science® Google Scholar
28 Wyskida K., Franik G., Pohl N. et al., Pentraxin 3 as a marker of endothelial dysfunction in young women with polycystic ovary syndrome (PCOS), Scandinavian Journal of Clinical and Laboratory Investigation. (2019) 79, no. 6, 419–423, https://doi.org/10.1080/00365513.2019.1637535, 2-s2.0-85068838785.
10.1080/00365513.2019.1637535
CAS PubMed Web of Science® Google Scholar
29 Kravchun P. G., Kadykova O. I., and Molotyagin D. G., Changes in pentraxin-3 level and its interaction with metabolic indices in patients with coronary artery disease and type 2 diabetes mellitus, Wiadomości Lekarskie. (2019) 72, no. 2, 181–185.
10.36740/WLek201902107
PubMed Google Scholar

Citing Literature

All articles

Pentraxin 3 Levels in Young Women with and without Polycystic Ovary Syndrome (PCOS) in relation to the Nutritional Status and Systemic Inflammation

Abstract

Conflicts of Interest

Open Research

Data Availability

References

Citing Literature

Figures

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Pentraxin 3 Levels in Young Women with and without Polycystic Ovary Syndrome (PCOS) in relation to the Nutritional Status and Systemic Inflammation

Abstract

Conflicts of Interest

Open Research

Data Availability

References

Citing Literature

Figures

References

Related

Information